[
    {
        "content": "* Core Laboratories NV qtrly \u200drevenue $166.2 million versus $143.5 million",
        "date": "10232017",
        "name": "Core Laboratories NV",
        "news_type": "topStory",
        "symbol": "CLB",
        "title": "BRIEF-Core Laboratories qtrly \u200drevenue $166.2 mln vs $143.5 mln "
    },
    {
        "content": "* Core Laboratories NV - q2 2017 revenue of $163.9 million  up 4 pct sequentially from its q1 2017 revenue",
        "date": "07242017",
        "name": "Core Laboratories NV",
        "news_type": "topStory",
        "symbol": "CLB",
        "title": "BRIEF-Core Laboratories Q2 profit of 52 cents/shr "
    },
    {
        "content": "NEW YORK  May 8 Billionaire investor David Einhorn on Monday called energy services provider Core Laboratories substantially overvalued and said its share price could drop to $62.",
        "date": "05082017",
        "name": "Core Laboratories NV",
        "news_type": "normal",
        "symbol": "CLB",
        "title": "Greenlight's Einhorn calls Core Labs shares 'way overvalued' "
    },
    {
        "content": "* CEO David Demshur's fy 2016 total compensation was $6.2 million versus $6.6 million in fy 2015 - sec filing  Source text: [http://bit.ly/2oer7bh] Further company coverage:",
        "date": "03242017",
        "name": "Core Laboratories NV",
        "news_type": "topStory",
        "symbol": "CLB",
        "title": "BRIEF-Core Laboratories CEO David Demshur's 2016 total compensation was $6.2 mln "
    },
    {
        "content": "* Q4 2016 revenue of $149.5 million up over 4% sequentially from Q3 2016",
        "date": "01252017",
        "name": "Core Laboratories NV",
        "news_type": "topStory",
        "symbol": "CLB",
        "title": "BRIEF-Core Laboratories reports Q4 earnings per share $0.35 "
    },
    {
        "content": "* Q3 earnings per share view $0.38  revenue view $146.2 million -- Thomson Reuters I/B/E/S",
        "date": "10192016",
        "name": "Core Laboratories NV",
        "news_type": "topStory",
        "symbol": "CLB",
        "title": "BRIEF-Core laboratories Q3 GAAP earnings per share $0.38 "
    },
    {
        "content": "* Second quarter EPS of $0.38 GAAP;  EPS of $0.35  excluding items",
        "date": "07202016",
        "name": "Core Laboratories NV",
        "news_type": "topStory",
        "symbol": "CLB",
        "title": "BRIEF-Core Laboratories N.V. Q2 revenue of $148.1 mln decreased 3.6 pct sequentially "
    },
    {
        "content": "* Core Laboratories NV files for stock shelf of up to 1.3 million shares of common stock - SEC Filing  Source text: http://1.usa.gov/1rGPeRj Further company coverage:",
        "date": "05112016",
        "name": "Core Laboratories NV",
        "news_type": "topStory",
        "symbol": "CLB",
        "title": "BRIEF-Core laboratories NV files for stock shelf of up to 1.3 mln shares "
    },
    {
        "content": "* Commenced a registered underwritten public offering of 1 300 000 shares of its common stock",
        "date": "05112016",
        "name": "Core Laboratories NV",
        "news_type": "normal",
        "symbol": "CLB",
        "title": "BRIEF-Core Laboratories commences underwritten public offering of 1.3 mln shares "
    }
]